Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

PHAR 100 – Introduction to Pharmacology Final Exam, Exams of Pharmacology

PHAR 100 – Introduction to Pharmacology Final Exam

Typology: Exams

2024/2025

Available from 07/11/2025

lec-douglas-levis
lec-douglas-levis 🇺🇸

121 documents

1 / 12

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
PHAR 100 – Introduction to Pharmacology Final Exam University of North Carolina at
Chapel Hill (UNC) Academic Year 2025-2026
Path |of |drug |from |when |it |enters |to |exits |the |body |- |answers1. |Absorption
2. |Distribution
3. |Metabolism
4. |Excretion
Absorption |- |answersthe |movement |of |the |drug |from |the |site |of |administration |into |the |bloodstream
Distribution |- |answersthe |movement |of |a |drug |from |the |blood |to |the |site |of |action |and |other |tissues
Metabolism |- |answersthe |conversion |of |a |drug |to |a |different |chemical |compound.
Excretion |- |answersmoving |of |the |drug |and |its |metabolites |out |of |the |body
Routes |of |drug |administration |- |answers1. |Topical
- |On |the |skin
-Transdermal
-Inhalation
2. |Enteral
-Oral
-Suppository
-Buccal
3.Parenteral
-IV
-IM
-Subcutaneous
Why |and |how |do |adverse |drug |reactions |occur? |- |answersExample: |a |receptor |is |activated |in |a |blood |
vessel |by |a |drug |designed |to |treat |hypertension. |The |rector |is |activated |by |the |ligand |that |is |bound |to
|it, |and |the |blood |pressure |is |lowered. |However, |this |receptor |may |located |in |other |areas |of |the |
pf3
pf4
pf5
pf8
pf9
pfa

Partial preview of the text

Download PHAR 100 – Introduction to Pharmacology Final Exam and more Exams Pharmacology in PDF only on Docsity!

PHAR 100 – Introduction to Pharmacology Final Exam University of North Carolina at

Chapel Hill (UNC) Academic Year 2025-

Path |of |drug |from |when |it |enters |to |exits |the |body |- |answers1. |Absorption

  1. |Distribution
  2. |Metabolism
  3. |Excretion Absorption |- |answersthe |movement |of |the |drug |from |the |site |of |administration |into |the |bloodstream Distribution |- |answersthe |movement |of |a |drug |from |the |blood |to |the |site |of |action |and |other |tissues Metabolism |- |answersthe |conversion |of |a |drug |to |a |different |chemical |compound. Excretion |- |answersmoving |of |the |drug |and |its |metabolites |out |of |the |body Routes |of |drug |administration |- |answers1. |Topical
  • |On |the |skin -Transdermal -Inhalation
  1. |Enteral -Oral -Suppository -Buccal 3.Parenteral -IV -IM -Subcutaneous Why |and |how |do |adverse |drug |reactions |occur? |- |answersExample: |a |receptor |is |activated |in |a |blood | vessel |by |a |drug |designed |to |treat |hypertension. |The |rector |is |activated |by |the |ligand |that |is |bound |to |it, |and |the |blood |pressure |is |lowered. |However, |this |receptor |may |located |in |other |areas |of |the |

body. |The |subsequent |activation |of |this |receptor |in |other |areas |of |the |body |is |an |example |of |an | adverse |effect. Adverse |effects |- |answers1. |Extension |of |therapeutic |effect

  1. |Unrelated |to |main |drug |action
  2. |Allergic |reaction
  3. |Dependence |and |addiction
  4. |Teratogenesis
  5. |Adverse |biotransformation |reactions Why |does |drug |variability |exist |- |answers1. |Genetic |Factors
  6. |Environmental |factors
  7. |Diseased |states |(cardiovascular |or |kidney |disease |for |example)
  8. |Altered |Physiological |state -pregnant |or |elderly
  9. |Other |drugs |present |(competition) The |process |of |developing |a |new |drug |- |answers1. |Pre-clinical |testing -safety |and |potential |efficacy |in |lab |animals
  10. |Phase |I |Clinical |Trial -safety |and |tolerability |in |healthy |volunteers
  11. |Phase |II | -effectiveness |and |safety |in |a |small |number |of |patients
  12. |Phase |III -effectiveness |and |safety |in |a |large |number |of |patients
  13. |Phase |IV -post |market |surveillance |for |adverse |effects |and |safety

|When |CB1 |is |activated |by |THC |or |anandamide, |the |release |of |excitatory |neurotransmitters |is | inhibited |, |which |explains |the |depressive |CNS |effects |of |cannabis. CB1 |Receptors |- |answersFound |primarily |in |the |brain |but |also |throughout |the |body. |High |density |in | specific |brain |regions. Ex; |high |density |in |hippocampus |may |mediate |the |decrease |in |memory |and |learning CB2 |Receptors |- |answersfound |mainly |outside |the |brain |in |immune |cells |(lymphocytes), |may |be | involved |in |inflammation CNS |stimulants |- |answersstimulate |the |central |nervous |system ex: |caffeine, |amphets, |cocaine CNS |depressants |- |answersSubstances |that |slow |down |the |body's |functions, |including |heart |and | breathing |rates. ex: |sedative |hypnotics, |alcohol TD50 |- |answerstoxic |dose |in |50% |of |the |population Hallucinogens |- |answersLSD, |MDMA Therapeutic |Index |- |answersTD50/ED50- |the |range |of |plasma |concentrations |where |the |drug |is | effective |but |drug |toxicities |do |not |usually |occur. Opiates |- |answersdepress |neural |activity, |temporarily |lessening |pain |and |anxiety ex: |morphine, |codeine, |heroin ED50 |- |answersEffective |dose |in |50% |of |the |population Cytochrome |p450 |- |answersThe |general |name |for |a |large |class |of |enzymes |that |play |a |significant |role | in |drug |metabolism |and |drug |interactions. |Responsible |for |biotransforming |about |50% |of |all |drugs | used |clinically. Issue |with |taking |multiple |medications |simultaneously |- |answersCytochrome |p450 |is |responsible |for | the |biotransformation |of |multiple |medications. |If |someone |is |taking |two |or |more |drugs |metabolized | by |this |enzyme, |interaction |effects |could |occur |and |competition |for |the |receptor, |which |may |lead |to | toxicity. glutamate |- |answersprimary |excitatory |neurotransmitter |in |the |brain GABA |- |answersthe |primary |inhibitory |neurotransmitter |in |the |brain

acetylcholine |- |answersproduces |an |excitatory |CNS |response. |Acts |on |cholinergic |receptors muscarinic |receptors |- |answersinvolved |in |learning, |memory |and |cognitive |function. |Loss |of |these | neurons |is |thought |to |be |linked |with |Alzheimers |disease. nicotinic |receptors |- |answerscholinergic |receptors |that |also |respond |to |stimulation |by |nicotine catecholamines |- |answersdopamine, |norepinephrine, |epinephrine serotonin |- |answersA |neurotransmitter |that |affects |hunger, |sleep, |arousal, |and |mood. |Hyperactivity |is | involved |in |anxiety, |hypo-activity |involved |with |depression. opioid |peptides |- |answersenkephalins, |endorphins, |dynorphins Factors |affecting |substance |abuse |- |answers1. |Genetics

  1. |Co-existing |disorders
  2. |Environmental |risk |factors
  3. |Developmental |aspects |(childhood |abuse |etc.) The |dopamine |hypothesis |- |answersThis |hypothesis |suggests |that |drugs |of |abuse |increase |dopamine | in |the |reward |systems |of |the |brain |(i.e. |the |limbic |system). Classification |of |why |drugs |can |become |addictive |- |answers1. |Reward |(increase |dopamine)
  4. |Novelty |(euphoria)
  5. |Reduce |anxiety Nicotine |mechanism |of |action |- |answersacts |on |nicotinic |receptors, |thus |increases |psychomotor | activity, |cognitive |function |and |memory Caffeine |mechanism |of |action |- |answersadenosine |receptor |antagonist, |stimulates |GABAergic |neurons |that |then |inhibit |dopamine |release. four |main |effects |of |amphetamines |- |answers1. |excitation |(overstimulation)
  6. |euphoria |and |sense |of |reward
  7. |temp |regulation |and |appetite |suppression
  8. |increase |in |aggressive |behaviour |and |mood |swings Clinical |uses |of |amphetamines |- |answersADHD, |narcolepsy amphetamine |mechanism |of |action |- |answersblocks |VMAT, |increases |norepinephrine, |dopamine |at | the |synapse

Gram-negative |bacteria |- |answersBacteria |that |have |complex |cell |walls |with |a |thin |peptidoglycan | layer, |and |an |outer |membrane. |Very |toxic |and |hard |to |treat. Broad |spectrum |antibiotics |- |answersaffect |a |broad |range |of |gram-positive |or |gram-negative |bacteria ex: |tetracyclines Narrow |spectrum |antibiotics |- |answersEffective |against |specific |bacteria ex: |penicillin |G Fluroquinolones |- |answersinhibit |bacterial |DNA |synthesis ex: |ciprofloxacin Penicillins |and |cephalosporins |- |answersinhibiting |transpeptidase, |causing |the |cell |wall |to |lyse |and | inhibiting |cell |wall |formation tetracyclines |- |answersinhibits |bacterial |protein |synthesis |by |binding |to |the |30S |ribosomal |subunit ex: |doxycycline macrolides |- |answersinhibit |protein |synthesis |by |binding |to |the |50S |ribosomal |subunit ex: |erythromycin, |azithromycin sulfonamides |- |answersblock |folate |metabolism |by |inhibiting |PABA |incorporation |into |dihydropteroic | acid trimethoprim |- |answersblock |folate |metabolism |by |inhibiting |dihydrofolic |acid |reductase How |does |antibiotic |resistance |occur? |- |answersEvolution: |Antibiotics |kill |the |bad |bacteria, |and |the | good |bacteria |that |protects |the |body |from |infection. |the |bacteria |become |drug |resistant, |and |can | take |over |and |give |the |resistance |to |other |bacterial |cells. | Also: |misuse |of |antibiotics |clinically |(over-prescription |or |misdiagnosis) |and |antibiotics |in |the | environment |(through |agriculture) which |penicillin |is |resistant |to |penicillinase? |- |answersMethicillin

contraceptives |mechanism |of |action |- |answersrelease |of |GnRH |is |inhibited |from |the |hypothalamus, | pituitary |is |not |stimulated |to |release |FSH |and |LH. |Progestins |alter |the |secretions |of |endocervical | gland, |so |sperm |migration |is |not |optimal, |implantation |does |no |occur. adverse |effects |of |contraceptives |- |answers-blood |clots -heart |attack -stroke -hypertension benefits |of |contraceptives |- |answers-reduced |risk |of |ovarian |cysts -reduced |risk |of |cervical |and |endometrial |cancer -reduced |incidence |of |ectopic |pregnancy -less |anemia -less |acne Progestin |only |contraceptives |- |answersIUD, |norplant, |mini-pill, |depo-provera progestin |and |estrogen |- |answersfixed, |multiphasic, |and |continuous |oral |pills, |transdermal |patch gossypol |- |answersAn |ingredient |in |cottonseed |oil |that, |when |injected |or |implanted, |may |inhibit | sperm |production |and |was |effective |in |99% |of |subjects grandparenting |- |answersnew |regulations |don't |apply |to |drugs |already |on |the |market Internal |Analgesics |- |answersSalicylates Acetaminophen Ibuprofen antihistamines |- |answersmedicines |that |reduce |the |production |of |histamines antacids |- |answerssystemic-absorbed |by |GI |tract, |causing |systemic |alkalosis non-systemic- |do |not |cause |systemic |alkalosis drugs |that |target |(inhibit) |stomach |acid |secretion |- |answersProton |pump |inhibitors, |H2 |(histamine) | inhibitors decongestants |- |answersconstrict |blood |vessels |of |nasal |passages |and |limit |blood |flow, |which |causes | swollen |tissues |to |shrink |so |that |air |can |pass |more |freely |through |the |passageways cough |suppressants |- |answersperipheral-block |nerve |endings |in |the |throat

-pregnancy, |menstruation -periods |of |hard |physical |work -stress -hypothyroidism -fever -tissue |wasting |disorders Vitamin |A |- |answersgrowth |and |development, |rhodopsin |required |for |night |vision Vitamin |E |- |answersessential |for |many |reactions, |and |is |an |antioxidant |that |protects |cells |(in |the | cardiovascular |system) |from |free |radicals Vitamin |D |- |answersincrease |absorption |of |calcium |and |phosphate, |regulate |calcium |levels Vitamin |C |- |answerscontributes |to |the |framework |that |holds |cells |together, |required |for |bone |and | teeth |formation, |helps |absorb |iron B |vitamins |- |answersfolic |acid |and |B12 |work |together |in |the |synthesis |of |red |blood |cells food |preservatives |- |answersanti-bacterials -smoke -antibiotics -sodium |nitrite antioxidants -water |soluble: |prevents |browning |of |fruit -lipid |soluble: |prevents |fats |from |becoming |rancid coloring |agents |- |answers-added |to |products |in |order |to |enhance |the |appearance, |toxicity |rare |but |if | allergic |to |aspirin |allergic |to |tartrazine texture |agents |- |answersimprove |texture |of |food ex: |silicate, |gums, |agar flavouring |- |answerssubstances |such |as |artificial |flavourings, |and |smoke |used |to |enhance |taste usually |non |toxic |except |for |MSG |which |causes |tightening |of |muscles, |headache, |nausea sweetners |- |answersaspartame, |saccharin, |improve |sweetness |without |adding |extra |sugar

environmental |toxicant |- |answerschemical |that |is |released |into |the |environment |and |can |produce | adverse |health |effects |on |living |organisms acute |toxicity |- |answersadverse |effects |that |occur |within |a |short |period |after |exposure |to |a |toxicant chronic |toxicity |- |answersadverse |effects |that |occur |some |time |after |exposure |to |a |toxicant |or |after | extended |exposure |to |the |toxicant common |environmental |toxicants |- |answers1. |Air |pollution

  1. |Particulate |matter
  2. |Gaseous |air |pollutants DDT |- |answersincrease |neuronal |sensitivity, |increases |CNS |stimulation Organophosphorous |(malathion) |- |answersvery |toxic |to |humans: |irreversibly |inhibits | acteylcholinesterase |thus |acetylcholine |cannot |break |down |and |Ach |increases |in |the |nervous |system | which |leads |to |decreased |respiration, |blurry |vision |and |incontinence TCDD |- |answersherbicide |that |binds |to |aryl |hydrocarbon |receptor |which |is |involved |in |expression |of | many |genes adverse |effects |of |TCDD |- |answerspoisoning |manifests |as |chloracne, |and |may |cause |stillbirths/defects Paraquat |- |answersherbicide |that |causes |immediate |burns |to |mouth |and |stomach, |targets |the |lungs lead |toxicity |- |answerscan |cause |lead |encephalopathy |and |poor |motor |coordination chelating |agents |- |answersMedications |that |bind |with |heavy |metals |in |the |body |and |create |a | compound |that |can |be |eliminated; |used |in |cases |of |ingestion |or |poisoning. Lead |chelator |- |answersEDTA carcinogenesis |- |answers1. |Initiation -genetic |change
  3. |Promotion -cell |multiplication
  4. |Progression -malignancy Goals |of |chemotherapy |- |answersprevent, |cure, |control, |relieve alkylating |agents |- |answersprevent |DNA |replication mitotic |inhibitors |- |answersprevent |cell |division hormones |and |hormone |antagonists |- |answerscontrol |hormones |for |cancers |mediated |by |hormones, | ex: |thyroid |cancer